GGrantIndex
← Leaderboards

Howard L McLeod

Washington University

Google Scholar ↗PubMed ↗ORCID ↗
$5,278,684
Attributed
$7,424,897
Total exposure
8
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.9M · FY2005–19
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$24,848,956 · 9

By mechanism

U01$17,424,059 · 3
R01$3,112,865 · 1
P50$2,809,648 · 2
P30$875,345 · 1
R21$627,039 · 2

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Pharmacogenetics”

Research focus

PharmacogeneticsPharmaceutical PreparationsGenesGenetic PolymorphismPhenotypeGeneticDrug MetabolismBiological ModelsVariantResourcesResponseIn VitroHuman Genetic Material TagGenetic VariantHuman Population GeneticsCandidate Disease GeneAntineoplastic AgentsFda ApprovedEtiologyEuropeanFollow-UpAmericanClinical TrialsAsians

Grant awards (40)

Genetic Etiology of Cancer Drug Response$399,257
R01 · FY2019 · CA
Genetic Etiology of Cancer Drug Response$67,486
R01 · FY2019 · CA
Genetic Etiology of Cancer Drug Response$411,539
R01 · FY2018 · CA
Genetic Etiology of Cancer Drug Response$436,055
R01 · FY2017 · CA
Genetic Etiology of Cancer Drug Response$396,756
R01 · FY2015 · CA
Genetic Etiology of Cancer Drug Response$454,879
R01 · FY2014 · CA
Genetic Etiology of Cancer Drug Response$446,811
R01 · FY2013 · CA
Genetic Etiology of Cancer Drug Response$500,082
R01 · FY2012 · CA
Functional Polymorphism Analysis in Drug Pathways$1,964,305
U01 · FY2009 · GM · contact PI
CORE--APPLIED GENOMICS$444,920
P50 · FY2009 · HL · contact PI
Pharmacogenetics of Post-ACS Therapy$444,920
P50 · FY2009 · HL · contact PI
Functional Polymorphism Analysis in Drug Pathways$1,907,329
U01 · FY2008 · GM · contact PI
Core--Pharmacology Facility$271,621
P30 · FY2008 · CA · contact PI
CORE--APPLIED GENOMICS$253,287
P50 · FY2008 · HL · contact PI
PHARMACOGENETICS OF POST-ACS THERAPY$247,802
P50 · FY2008 · HL · contact PI
Functional Polymorphism Analysis in Drug Pathways$1,907,323
U01 · FY2007 · GM · contact PI
Core--Pharmacology Facility$284,620
P30 · FY2007 · CA · contact PI
CORE--APPLIED GENOMICS$246,000
P50 · FY2007 · HL · contact PI
PHARMACOGENETICS OF POST-ACS THERAPY$240,951
P50 · FY2007 · HL · contact PI
Functional Polymorphism Analysis in Drug Pathways$1,937,460
U01 · FY2006 · GM · contact PI
CORE--APPLIED GENOMICS$238,835
P50 · FY2006 · HL · contact PI
PHARMACOGENETICS OF POST-ACS THERAPY$233,934
P50 · FY2006 · HL · contact PI
Ovarian Cancer Pharmacogenetics$142,806
R21 · FY2006 · CA · contact PI
Core--Pharmacology Facility$109,527
P30 · FY2006 · CA · contact PI
Functional Polymorphism Analysis in Drug Pathways$2,002,493
U01 · FY2005 · GM
CORE--APPLIED GENOMICS$231,878
P50 · FY2005 · HL
PHARMACOGENETICS OF POST-ACS THERAPY$227,121
P50 · FY2005 · HL
Ovarian Cancer Pharmacogenetics$157,638
R21 · FY2005 · CA
Core--Pharmacology Facility$106,337
P30 · FY2005 · CA
Functional Polymorphism Analysis in Drug Pathways$1,592,527
U01 · FY2004 · GM
Pharmacogenetics advanced colorectal cancer$158,540
R21 · FY2004 · CA
Core--Pharmacology Facility$103,240
P30 · FY2004 · CA
Functional Polymorphism Analysis in Drug Pathways$1,963,077
U01 · FY2003 · GM
Pharmacogenetics advanced colorectal cancer$168,055
R21 · FY2003 · CA
Functional Polymorphism Analysis in Drug Pathways$2,054,116
U01 · FY2002 · GM
POPULATION GENETICS AND DRUG METABOLISM$0
U01 · FY2002 · GM
POLYMORPHISM AND DRUG METABOLISM IN INTESTINAL NEOPLASMS$0
U01 · FY2002 · GM
Functional Polymorphism Analysis in Drug Pathways$2,095,429
U01 · FY2001 · GM
POPULATION GENETICS AND DRUG METABOLISM$0
U01 · FY2001 · GM
POLYMORPHISM AND DRUG METABOLISM IN INTESTINAL NEOPLASMS$0
U01 · FY2001 · GM